SCHEMBL3385124

SCHEMBL3385124

c1csc(-c2csc3ncnc(NCC4CC4)c23)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.62
ALDH1A1 P00352 3/20 0.62
TNF P01375 2/20 0.62
NOD1 Q9Y239 2/20 0.62
POLB P06746 1/20 0.62
PKM P14618 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
HTT P42858 7/20 0.58
LMNA P02545 4/20 0.58
STAT3 P40763 1/20 0.52
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 2/20 0.47
ADRB3 P13945 3/20 0.45
FLT3 P36888 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368375 0.83 LMNA (0.65) SMN1; SMN2ALDH1A1TNFNOD1HTT
SCHEMBL2368835 0.81 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL3387875 0.81 SMN1; SMN2 (0.71) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL2369385 0.80 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL2369043 0.80 SMN1; SMN2 (0.73) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL2369025 0.78 LMNA (0.61) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL5804881 0.78 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL2369091 0.78 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL3382531 0.76 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1TNFNOD1POLB
SCHEMBL6641883 0.75 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1TNFNOD1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 SMN1; SMN2 1520/4885ALDH1A1 247/4885TNF 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.